{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:9875401",
      "entity_text" : "rivaroxaban",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:2157",
      "entity_text" : "amiodarone",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0800" ],
      "CellLine" : [ "cellosaurus:CVCL_AV82" ],
      "Organ" : [ "uberon:UBERON:0000105" ],
      "Species" : [ "taxonomy:9606" ],
      "CellType" : [ "cl:CL:0000813" ]
    }
  },
  "verbose_text" : "The drug-drug interaction between amiodarone and rivaroxaban is expected to lead to an increase of AUC for rivaroxaban> = twofold but < = fivefold.18 In our patient, his eGFR approaches the threshold for CKD Stage 4, and this would have further increased the rise in plasma levels in an additive manner.",
  "reading_complete" : "2020-08-03T11:16:35Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T11:15:46Z",
  "trigger" : "interaction",
  "evidence" : [ "interaction between amiodarone and rivaroxaban" ],
  "pmc_id" : "7141729",
  "score" : 0
}